1	Allogeneic haemopoietic transplantation for acute
2	myeloid leukaemia in second complete remission: A
3	registry report by the Acute Leukaemia Working
4	Party of the EBMT
5	
6 7 8	Running title: Allograft in second remission acute myeloid leukaemia
9	Maria H. Gilleece ¹ , Myriam Labopin ² , Bipin N. Savani ³ , Ibrahim
10	Yakoub-Agha ⁴ , Gerard Socié ⁵ , Tobias Gedde-Dahl ⁶ , Didier
11	Blaise ⁷ , Jennifer L. Byrne ⁸ , Charles Craddock ⁹ , Jan J.
12	Cornelissen ¹⁰ , William Arcese ¹¹ , Edouard Forcade ¹² , Charles
13	Crawley ¹³ Emmanuelle Polge ¹⁴ , Mohamad Mohty ¹⁵ , Arnon
14	Nagler ¹⁶ .
15	
16	Corresponding Author: Maria H. Gilleece MD(Res)
17	Department of Haematology, Bexley Wing, St James's
18	University Hospital, Leeds. LS9 7TF. United Kingdom
19	Tel: +441132068433
20	mgilleece@nhs.net
21	
22	Author affiliations
23	1 Department of Haematology, Leeds Teaching Hospitals
24	Trust, Leeds, UK
25	

26 2 EBMT Paris study office/CEREST-TC, Paris, France.

- 28 3 Division of Hematology/Oncology, Vanderbilt University
- 29 Medical Center, Nashville, TN, USA.
- 30
- 31 4 CHU de Lille, LIRIC, INSER U995, Université de Lille,
- 32 Lille, France.
- 33
- 34 5 Hematologie / Transplantation, Hôpital St Louis, Paris
- 35 CEDEX 10, France
- 36
- 37 6 Section for Hematology, Oslo University Hospital,
- 38 Rikshospitalet, Oslo, Norway.
- 39
- 40 7 Programme de Transplantation & Therapie Cellulaire,
- 41 Centre de Recherche en Cancérologie de Marseille,
- 42 Institut Paoli Calmettes, Marseille, France.
- 43
- 44 8 Faculty of Medicine and Health Sciences, University of
- 45 Nottingham, Nottingham UK.
- 46
- 47 9 Queen Elizabeth Medical Centre, University Hospital
- 48 Birmingham NHS Trust, Department of Haematology,
- 49 Birmingham, United Kingdom;
- 50

- 51 10 Erasmus MC Cancer Institute, University Medical
- 52 Center Rotterdam, Department of Haematology,
- 53 Rotterdam, Netherlands

- 55 11 Tor Vergata University of Rome, Policlinico
- 56 Universitario Tor Vergata, Stem Cell Transplant Unit,
- 57 Rome, Italy
- 58
- 59 12 Service Hématologie Clinique et Thérapie Cellulaire
- 60 Hôpital Haut-Lévêque CHU Bordeaux, France
- 61
- 62 13 Addenbrookes Hospital, Department of Haematology,
- 63 Cambridge, United Kingdom
- 64
- 65 14 Acute Leukemia Working Party, European Society for
- 66 Blood and Marrow Transplantation Paris Study
- 67 Office/European Center for Biostatistical and
- 68 Epidemiological Evaluation in Hematopoietic Cell
- 69 Therapy (CEREST-TC), Paris, France.
- 70
- 71 15 Hôpital Saint Antoine, INSERM UMR 938, Paris,
- 72 France; ⁵Université Pierre et Marie Curie, Paris, France;
- 73
- 74 16 Hematology Division, Chaim Sheba Medical Center,
- 75 Tel Hashomer, Israel.

76

77 Competing interests statement

- 79 Maria H Gilleece Travel grant, advisory board and
- 80 speaker fees Jazz Pharmaceuticals
- 81 Myriam Labopin Nil
- 82 Bipin Savani Honoraria from JAZZ Pharmaceuticals and
- 83 Therakos
- 84 Ibrahim Yakoub-Agha Nil
- 85 Gerard Socié Nil
- 86 Tobias Gedde-Dahl Nil
- 87 Didier Blaise- Nil
- 88 Jennifer Byrne advisory board and speaker fees Pfizer,
- 89 Novartis and Jazz Pharmaceuticals.
- 90 Charles Craddock Nil
- 91 Jan.J. Cornelissen Nil
- 92 William Arcese Nil
- 93 Edouard Forcade Travel grant Neovil; Scientific expert
- 94 Novartis.
- 95 Charles Crawley Nil
- 96 Emmanuelle Polge Nil
- 97 Mohamad Mohty Nil
- 98 Arnon Nagler Nil

99 Abstract

100	Allogeneic	haemopoietic cell	transplant	(allo-HCT) may
-----	------------	-------------------	------------	----------------

- 101 be curative in acute myeloid leukaemia (AML) in second
- 102 complete remission (CR2) but the impact of reduced
- 103 intensity (RIC) versus myeloablative conditioning (MAC)
- 104 is uncertain. The Acute Leukaemia Working Party of the
- 105 European Society for Blood and Bone Marrow
- 106 Transplantation Registry studied an AML CR2 cohort
- 107 characterised by age \geq 18y, first allo-HCT 2007-2016,
- 108 available cytogenetic profile at diagnosis, donors who
- 109 were matched family, volunteer unrelated with HLA
- 110 antigen match 10/10 or 9/10 or haplo-identical. The 1879
- 111 eligible patients included 1010 (54%) MAC allo-HCT
- 112 recipients.
- 113
- 114 In patients <50 years (y), two year outcomes for MAC vs 115 RIC allo-HCT were equivalent with leukaemia free 116 survival (LFS) 54% for each, overall survival (OS), 61 vs 117 62%, non-relapse mortality (NRM) 18 vs 15% and graft 118 versus host disease relapse free survival (GRFS) 38 vs 119 42%. In patients ≥50y, 2y outcomes for MAC vs RIC allo-120 HCT were equivalent for LFS 52 vs 49%, OS 58 vs 55% 121 and GRFS 42.4 vs 36%. However, NRM was significantly 122 inferior after MAC allo-HCT, 27 vs 19% (P=0.01) despite 123 worse cGVHD after RIC-allo (32 vs 39%). These data

- 124 support the need for ongoing prospective study of
- 125 conditioning intensity and GVHD mitigation in AML.
- 126
- 127 **FUNDING:** This study was supported by the European
- 128 Society for Blood and Bone Marrow Transplantation
- 129 funded by annual subscription from the constituent
- 130 transplant centres.
- 131

132 Introduction

- 133 Acute myeloid leukaemia (AML) is grouped into good,
- 134 intermediate and adverse genetic risk categories that
- 135 may be combined with response rates to induction
- therapy to predict survival outcomes (1–3). Integration of
- 137 relapse rates, procedural mortality of allogeneic
- 138 haemopoietic cell transplant (allo-HCT) and projected
- 139 success rates of salvage regimens permits an estimate of
- 140 the potential benefit and optimal timing of an allo-HCT as
- 141 consolidation therapy (4–6,1). Consequently, for patients
- 142 achieving first complete remission (CR1) it is
- 143 conventional to offer allo-HCT in adverse and
- 144 intermediate risk disease where the relapse risk is more
- 145 than 45% and there are clear benefits to transplantation
- 146 (7,8). Allo-HCT is deferred to CR2 for patients with good
- 147 risk disease despite a relapse risk of up to 35%, since

- 148 many will be cured without the hazards of allo-HCT (5).
- 149 However, management of an individual patient requires a
- 150 personalised amalgamation of risk of relapse, transplant
- 151 related mortality and access to a suitable donor
- 152 (1,6,9,10). Thus, patients with high HCT comorbidity
- 153 index scores and a mismatched volunteer donor may
- 154 wish to defer allo-HCT (11,12).
- 155
- 156 While it is often assumed that those patients who relapse
- 157 subsequent to a first CR may be duly salvaged and
- 158 offered allo-HCT in CR2, this does not square with reality
- 159 (13–16). Breems *et al* studied a cohort of 1540 patients
- 160 with newly diagnosed AML enrolled on clinical trials
- 161 between 1987 and 2001 and established that the duration
- 162 of CR1, age at relapse, cytogenetic risk factor at
- 163 diagnosis and a prior allo-HCT could be used to predict
- the likelihood of CR2 (4). Those patients who did achieve
- 165 CR2 were shown to have a survival benefit from allo-HCT
- 166 compared to alternative therapies. Subsequent studies
- 167 have largely confirmed these findings (Table 1) (17–21).
- 168
- 169 Since no other large series address the impact of
- 170 conditioning regimen intensity on the outcomes of HCT in
- 171 patients with AML CR2, we have analysed an eligible
- 172 cohort of patients for whom data had been deposited in

- 173 the registry of the European Society for Blood and
- 174 Marrow Transplantation (EBMT).
- 175
- 176 Methods
- 177 Study design and data collection
- 178 This was a multicentre, retrospective registry study by the
- 179 Acute Leukaemia Working Party (ALWP) of the EBMT.
- 180 The EBMT is a voluntary group that represents more than
- 181 600 transplant centers, predominantly European, which
- are required to report all consecutive HCT and follow-up
- 183 once a year. EBMT Med A/B standardized data collection
- 184 forms are completed and submitted to the registry by
- 185 transplant center personnel following written informed
- 186 consent from patients in accordance with center ethical
- 187 research guidelines (22). Accuracy of data is assured by
- 188 the individual transplant centers and by quality control
- 189 measures such as regular internal and external audits.
- 190 Since January 1, 2003, all transplant centers have been
- 191 required to obtain written informed consent prior to data
- 192 registration with the EBMT, following the Helsinki
- 193 Declaration of 1975. The study was approved by the
- 194 ALWP.

195 Eligibility criteria

- 196 Eligibility criteria were: age ≥18y, first allo-HCT 2007-
- 197 2016, diagnosis of AML CR2, availability of cytogenetic
- 198 profile at diagnosis.
- 199 Cytogenetic status was classified using MRC UK criteria
- 200 while any identified molecular markers at diagnosis were
- also noted (23). Donors were restricted to a human
- 202 leukocyte antigen (HLA) matched family donor (MFD),
- 203 volunteer unrelated donor with HLA match 10/10 (VUD)
- 204 or 9/10 match (MMVUD) or haplo-identical (Haplo ID)
- 205 donor. Graft source included peripheral blood stem cells
- 206 (PBSC) or bone marrow (BM) grafts. Engraftment was
- 207 assessed by conventional EBMT standards (22).
- 208
- 209 Intensity of conditioning was classified in accordance with
- 210 published criteria while the more recently adopted
- 211 regimens Treosulfan/Fludarabine (TF) and
- 212 Thiotepa/Busulfan/Fludarabine (TBF) were considered as
- 213 myeloablative when the busulfan dose was at least 9.6
- 214 mg/kg (24–26).

215 Statistical analysis

- 216 Patient, disease, and transplant-related characteristics for
- 217 the two cohorts (MAC or RIC) were compared by using χ^2
- 218 statistics for categorical variables and the Mann-Whitney
- 219 test for continuous variables. The primary endpoint was

- 220 leukemia-free survival (LFS). Secondary endpoints were
- 221 relapse incidence (RI), non-relapse mortality (NRM),
- 222 overall survival (OS), acute graft-versus-host disease
- 223 (aGVHD), chronic graft-versus-host-disease (cGVHD)
- 224 and GVHD-free/relapse-free survival (GRFS). LFS was
- 225 defined as survival with no evidence of relapse or
- progression. Relapse was defined as the presence of 5%
- 227 BM blasts and/or reappearance of the underlying
- 228 disease. NRM was defined as death without evidence of
- relapse or progression. OS was defined as the time from
- 230 allo-HCT to death, regardless of the cause. GRFS was
- 231 defined as events excluding grade 3-4 acute GVHD,
- 232 extensive chronic GVHD, relapse, or death in the first
- 233 post-HCT year (27–29).
- 234
- 235 Cumulative incidence was used to estimate the endpoints
- 236 of NRM, RI, acute and chronic GVHD to accommodate
- 237 for competing risks. To study acute and chronic GVHD,
- 238 we considered relapse and death to be competing
- 239 events. Probabilities of OS, LFS, and GRFS were
- 240 calculated using the Kaplan–Meier method. Univariate
- analyses were done using the Gray's test for cumulative
- 242 incidence functions and the log rank test for OS, GRFS,
- and LFS. Cox proportional hazards model was used for
- 244 multivariate regression. All variables differing significantly

245	between the 2 groups or factors associated with one
246	outcome in univariate analysis were included in the Cox
247	model. In order to test for a centre effect, we introduced a
248	random effect or frailty for each center into the model
249	(30,31). We studied 2 different Cox models in patients
250	aged under 50 or 50 years and above at the time of allo-
251	HCT. Results were expressed as the hazard ratio (HR)
252	with a 95% confidence interval (95% CI). Proportional
253	hazards assumptions were checked systematically for all
254	proposed models using the Grambsch-Therneau
255	residual-based test. All tests were 2-sided. The type I
256	error rate was fixed at 0.05 for the determination of
257	factors associated with time-to-event outcomes. Analyses
258	were stratified by age at allo-HCT (less or \geq 50 years) and
259	declared measurable residual disease (MRD) status at
260	HCT. Statistical analyses were performed with SPSS
261	24.0 (SPSS Inc., Chicago, IL, USA) and R 3.4.0 (R Core
262	Team (2017). R: A language and environment for
263	statistical computing. R Foundation for Statistical
264	Computing; Vienna; Austria. <u>https://www.R-project.org/</u> .)
265 266	Results
267	Patient, disease and transplant characteristics

- A total of 1879 patients, 1013 male, from 230 transplant
- 269 centers were eligible. Patient, disease, donor and

- 270 transplant characteristics are detailed in Supplementary
- Table 1 (Table S1).
- 272 Median follow-up of surviving patients was 26.16 months
- 273 (m) (0.49 124.63). Approximately 95% of patients in
- each group had *de novo* AML at initial diagnosis.
- 275 MAC regimens were used in 1010 while 869 received
- 276 RIC allo-HCT. Time from diagnosis to transplant was
- 277 marginally longer in RIC allo-HCT recipients at a median
- 278 of 18.5 m (range 0.8-222.9) vs 17.7m (1.2-239.1)
- 279 (P=0.017) in MAC recipients.
- 280 Recipients of RIC allo-HCT compared to MAC allo-HCT
- 281 recipients were older (median age 57.3y (18.2-75.3) vs
- 282 42.8y, (18-72y) P<0.001), had a worse Karnofsky
- 283 performance status (P<0.001) and had a higher
- 284 proportion of adverse or intermediate cytogenetics at
- 285 diagnosis ($P < 10^{-3}$) (Table S1).
- 286 Family donors, whether MFD or Haplo-ID, were more
- 287 commonly available for MAC allo-HCT than RIC allo-HCT
- 288 recipients and accounted for half of the donors in the
- 289 MAC allo-HCT group. Conversely, unrelated donors,
- 290 particularly HLA 10/10 VUDs were more likely than family
- donors to be used in the RIC allo-HCT setting (P<0.0 01).
- 292 While PBSC was the preferred source of stem cells in
- 293 both conditioning groups, this was more pronounced in

- the RIC allo-HCT group with only 7.59% cases using BM
- 295 vs 24.78% in the MAC HCT group (P<0.001). A
- 296 preference for male donors was seen in both groups and
- 297 particularly so in RIC allo-HCT (P=0.005) (Table S1).
- 298 Transplant characteristics are shown in Table S1. T cell
- 299 depletion, whether with anti-thymocyte globulin or
- 300 alemtuzumab was applied in 47.01% MAC HCT and
- 301 70.59% RIC/NMA HCT (P < 0.001).
- 302 Regimens used for GVHD prophylaxis favoured
- 303 cyclosporine based approaches rather than tacrolimus or
- 304 post-transplant cyclophosphamide. Cyclosporine was
- 305 most often used in combination with methotrexate in MAC
- 306 HCT and alone or with mycophenolate mofetil in
- 307 RIC/NMA HCT (P<0.001).
- 308
- **309** Outcomes of transplantation
- 310 At 2y, the overall outcomes were LFS 52% (CI: 49.5 -
- 311 54.5), OS 58.7% (CI: 56.2 61.2), RI 28.9% (CI: 26.7 -
- 312 31.2), NRM 19% (CI: 17.2 21), GRFS 38.7% (CI: 36.2 -
- 313 41.1), cGVHD 37.2% (CI: 34.7 39.7) and extensive
- 314 cGVHD 15.9% (CI: 14.1 17.8) (Tables S2 and S3) Non-
- 315 relapse deaths were predominantly due to GVHD or
- 316 sepsis (Table S2).
- 317

- 318 Multivariate analysis was performed to examine the
- 319 impact of conditioning intensity as well as other
- 320 parameters believed to determine transplant outcomes.
- 321 Table S4 summarises the MVA for all patients. In this
- 322 cohort, no transplant outcome differed significantly by
- 323 conditioning intensity with the notable exception of NRM
- which favoured RIC Allo-HCT, (HR 0.65 95% CI 0.50-
- 325 0.84 P=0.001). However, when patients were divided by
- 326 age range <50y vs ≥50y this advantage to RIC ALLO-
- 327 HCT retained significance only in patients ≥50y (HR 0.54
- 328 CI 0.38-0.76 P < 0.001) (Tables 2 and 3). Thus, even in
- 329 patients selected as being fit for MAC Allo-HCT by their
- transplant team, we found excess NRM in older patients.
- This is supported by the increase in NRM that is seen
- 332 with increasing age in the <50y (HR 1.25 CI 1.01-1.53
- 333 P=0.034) as well as the ≥50y (HR 1.6 CI: 1.21-2.03
- 334 P=0.001) (Tables 2 and 3).
- 335
- 336 The other striking association with conditioning intensity
- 337 was also seen in patients ≥50y, but not in younger
- 338 patients, and this was an excess of cGVHD in those
- 339 undergoing RIC allo-HCT (HR 1.38 CI 1.03-1.85; P=0.03)
- 340 although this difference did not extend to extensive
- 341 GVHD (Table 3).
- 342

- 343 A decision to use reduced intensity rather than 344 myeloablative conditioning may be influenced by the age, 345 comorbidity and performance status of the patient (32-346 34). As well as the impact of increasing age as a 347 continuous variable on NRM, we also found an adverse 348 effect on GRFS which reached significance in patients 349 <50y (HR 1.13 CI 1.01-1.26 P=0.03) while remaining a 350 trend in older patients. Overall, older patients also had 351 worse LFS and OS (31-(32-34)33) (Table S4 and Table 352 3). 353 354 Karnofsky Performance Scores (KPS) >80% were 355 predictive of lower NRM in both age-groups. Additionally, 356 in patients ≥50y, KPS >80 predicted lower rates of 357 aGVHD and superior OS, LFS and GRFS (Table 3). 358 In accordance with other large studies of patients 359 transplanted in AML CR2 that have found better 360 transplant outcomes in those patients with longer duration 361 CR1, probably reflecting the innate aggressiveness of 362 disease, (17–20), we found that patients with longer 363 intervals from diagnosis to allo-HCT had superior RI, 364 LFS, OS and GRFS. (Table S4). 365 366 The distribution of cytogenetic risk groups at diagnosis
- 367 resembled the MRC and Japanese cohorts (17,18).

- 368 Patients with good risk cytogenetics at diagnosis fare
- 369 better after transplant than those with intermediate and
- 370 adverse risk cytogenetics (17–20) and our results are
- 371 confirmatory in a different data set and across all age
- 372 groups. (Supplementary Tables 4 and 5).
- 373 At 2y, OS following allo-HCT was 67.4, 56.8 and 37.9% in
- 374 good, intermediate and adverse risk cytogenetic groups
- 375 respectively. Overall, this compares favourably with the
- 376 5y OS of 35, 47 and 34% reported by Burnett in which
- 377 survival curves flattened between 2 and 3 years from
- 378 transplant, but emphasises the persistently poor outcome
- 379 due to relapse for patients with adverse karyotypes
- 380 (17,32,35,36).
- 381
- 382 Donor selection has historically had a major impact on
- 383 the outcomes of transplant, although the increasing use
- 384 of high resolution HLA typing and novel GVHD
- 385 prophylaxis strategies may be eroding the differences in
- 386 outcomes associated with unrelated versus matched or
- 387 haploidentical family donors (37–40). In this study we
- 388 found that donor characteristics retained a significant
- impact upon transplant outcomes (Tables 2 and 3).
- 390 MMVUD and Haplo-ID donors were associated with
- 391 increased rates of NRM and aGVHD II-IV and the use of

- 392 female donors was associated with higher rates of
- 393 extensive cGVHD.
- 394 In general in modern transplant practice PBSC is the
- 395 preferred stem cell source although faster engraftment
- 396 may be offset by increased risks of GVHD (41). We found
- 397 that the use of PBSC was associated with significantly
- 398 increased rates of cGVHD in both the <50y and the \geq 50y
- 399 (HR 1.784 CI 1.253-2.539, HR 1.683 CI 1.08-2.624) but
- 400 no improvements in OS or LFS in either group (Tables 2
- 401 and 3). Similar to our earlier study in AML CR1, (42),
- 402 TCD led to beneficial effects on GRFS, aGVHD and
- 403 cGVHD in <50y and to improvements in GRFS and
- 404 cGVHD in the ≥50y without detriment to RI, OS or LFS
- 405 suggesting that TCD reduces GVHD without increasing
- 406 relapse risks (Tables 2 and 3).
- 407
- 408 Finally, we looked for the impact of centre and year of
- 409 transplant but found no significant effect on transplant
- 410 outcomes (Tables 3 and 4).
- 411

412 Discussion

- 413
- 414 This large registry study tracked the effect of allo-HCT on
- 415 the post-transplant survival characteristics of 1879
- 416 patients with AML in CR2 in the modern era (2007-2016)
- 417 and investigated the impact of conditioning intensity on

- 418 outcomes in patients aged <50y or ≥50y. OS, LFS and
- 419 GRFS at 2y were 58.7%, 52% and 38.7%.
- 420 We established that in patients aged <50y, 2y OS was
- 421 61.1% vs 61.8% for MAC vs RIC allo-HCT (P=0.7) while
- 422 LFS was 53.9% vs 54.1% (P=0.61). Similarly, in patients
- 423 aged 50y or more at HCT, MAC allo-HCT and RIC allo-
- 424 HCT were equivalent with 2y OS of 58.3% vs 55.1%
- 425 (P=0.3) and LFS of 51.5% vs 49.3% (P=0.7). Multivariate
- 426 analysis confirmed that in patients <50y and \geq 50y,
- 427 intensity of conditioning made no significant difference to
- 428 OS, LFS or RI. However, in ≥50y, NRM rates were
- 429 significantly reduced following RIC allo-HCT and while
- 430 there was an increased risk of cGVHD this did not
- 431 manifest as extensive cGVHD. These observations
- 432 suggest overall equivalence of MAC and RIC regimens
- 433 and a rationale for further prospective study. This is in
- 434 keeping with our previous observations in AML CR1 but
- 435 contrasts with the outcomes of the Blood and Marrow
- 436 Transplant Clinical Trials Network (BMT CTN) 0901
- 437 prospective study of 272 patients with AML or
- 438 myelodysplasia in which high relapse rates in patients
- 439 receiving RIC Allo-HCT compared to MAC Allo-HCT led
- to premature study closure (42,43). Despite the caveat
- 441 that our current study is retrospective, it is a larger one,
- 442 encompassing a wider range of regimens and with longer

- 443 follow-up. Additionally, the outcomes of patients with AML
- 444 CR2 in the BMT CTN study are not specified.
- 445
- 446 Similar to earlier studies, we found that adverse factors
- 447 included increasing age, cytogenetics other than good
- 448 risk, poor performance status, shorter time intervals from
- 449 initial diagnosis to transplant and mismatched donor allo-
- 450 HCT (4,17,20).
- 451
- 452 Given the high rates of relapse, with overall 2y RI of
- 453 28.9%, there is a grave need for more active leukaemia
- 454 therapy. This might be addressed by sequential
- 455 chemotherapy approaches such as the FLAMSA based
- 456 regimens or by combining alkylating agents in the
- 457 conditioning regimen (26,44–46). Additionally, new agents
- 458 hold out the promise of higher CR rates and prospects for
- 459 maintenance therapies which may potentially be used in
- 460 conjunction with allo-HCT to improve survival in AML(47–
- 461 50). Immunotherapy approaches, while less advanced
- than for lymphoid malignancies also hold potential (51).
- 463
- 464 Our study is limited since it can only address the
- 465 outcomes of those patients who achieved CR2 and were
- 466 transplanted, thus not addressing the larger problem of
- 467 management of relapse after CR1. Likewise, we may only

- 468 speculate as to the reasons why allo-HCT was deferred
- 469 to CR2. We had insufficient data to draw conclusions
- 470 about the impact of comorbidity, MRD or molecular sub-
- 471 groups such as FLT3 ITD with or without NPM1
- 472 mutations (34,52–54). While MRD status was available in
- 473 67% patients, equally distributed across conditioning
- 474 groups, it had no confounding influence on the
- 475 relationship between conditioning intensity and transplant
- 476 outcomes.
- 477
- 478 However, we show improving survival outcomes after
- 479 allo-HCT in a large cohort of patients with AML CR2
- 480 treated in a recent time-frame while confirming that
- 481 existing prognostic indicators retain their value. These
- 482 data also provide fresh impetus for the prospective
- 483 comparison of the impact of conditioning intensity on allo-
- 484 HCT outcomes in AML CR2.
- 485

486 Acknowledgements

- 487 We thank all European Group for Blood and Marrow
- 488 Transplantation (EBMT) centres and national registries
- 489 for contributing patients to the study and data managers
- 490 for their superb work. The study was supported by the
- 491 European Blood & Marrow Transplantation funded by

- 492 annual subscription from the constituent transplant
- 493 centres.
- 494
- 495 Competing interests statement
- 496
- 497 Maria H Gilleece Travel grant, advisory board and
- 498 speaker fees Jazz
- 499 Myriam Labopin Nil
- 500 Bipin Savani Honoraria JAZZ and Therakos
- 501 Ibrahim Yakoub-Agha Nil
- 502 Gerard Socié Nil
- 503 Tobias Gedde-Dahl Nil
- 504 Didier Blaise- Nil
- 505 Jennifer Byrne advisory board and speaker fees Pfizer,
- 506 Novartis and Jazz
- 507 Charles Craddock Nil
- 508 Jan.J. Cornelissen Nil
- 509 William Arcese Nil
- 510 Edouard Forcade Travel grant Neovil; Scientific expert
- 511 Novartis.
- 512 Charles Crawley Nil
- 513 Emmanuelle Polge Nil
- 514 Mohamad Mohty Nil
- 515 Arnon Nagler Nil
- 516

517		
518		
519	Re	ferences
520		
521 522 523 524	1.	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016 Nov 28;129(4):424–47.
525 526 527	2.	Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016 Feb 4;374(5):422–33.
528 529 530 531 532	3.	Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2018 May 20;36(15):1486–97.
533 534 535 536	4.	Breems DA, Van Putten WLJ, Huijgens PC, Ossenkoppele GJ, Verhoef GEG, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Mar 20;23(9):1969–78.
537 538 539 540 541	5.	Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012 Oct;9(10):579–90.
542 543 544 545	6.	Appelbaum FR. Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2014;e327-333.
546 547 548 549 550	7.	Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10;301(22):2349–61.
551 552 553 554	8.	Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid

555 556		leukemia in young and middle-aged adults: benefits for whom? Blood. 2007 May 1;109(9):3658–66.
557 558 559 560	9.	Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010 Nov 25;363(22):2091–101.
561 562 563	10.	Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Feb 10;29(5):487–94.
564 565 566 567	11.	Cornelissen JJ, Versluis J, Passweg JR, van Putten WLJ, Manz MG, Maertens J, et al. Comparative therapeutic value of post- remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2015 May;29(5):1041–50.
568 569 570 571	12.	Gorin N-C, Giebel S, Labopin M, Savani BN, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplant. 2015 Dec;50(12):1495–502.
572 573 574	13.	Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013 Feb 14;121(7):1077–82.
575 576 577	14.	Gale RP, Lazarus HM. Correcting 2 more myths regarding transplants for AML in second remission. Blood. 2014 Jan 30;123(5):794.
576	14. 15.	transplants for AML in second remission. Blood. 2014 Jan
576 577 578 579		transplants for AML in second remission. Blood. 2014 Jan 30;123(5):794. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission?
576 577 578 579 580 581 582 583	15.	 transplants for AML in second remission. Blood. 2014 Jan 30;123(5):794. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia. 2014 Oct;28(10):1949–52. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN
576 577 578 579 580 581 582 583 584 585 586 586 587	15. 16.	 transplants for AML in second remission. Blood. 2014 Jan 30;123(5):794. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia. 2014 Oct;28(10):1949–52. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018 Jun 15; Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol

595 596		relapse: a retrospective study from the French AML Intergroup. Blood. 2014 Aug 21;124(8):1312–9.
597 598 599 600	20.	Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, et al. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017 Jun 1;123(11):2025–34.
601 602 603 604 605 606	21.	Slovak ML, Kopecky, KJ, Cassileth PA, Harrington, D.H., Theil, K.S., Mohamed, A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96 (13):4075- 83. 5. Leopold LH,. Blood. 96(13):4075–83.
607 608	22.	European Society for Blood and Marrow Transplantation [Internet]. [cited 2018 Mar 30]. Available from: www.ebmt.org
609 610 611 612 613 614 615	23.	Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010 Jul 22;116(3):354–65.
616 617 618 619	24.	Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009 Dec;15(12):1628–33.
620 621 622 623 624 625 626	25.	Shimoni A, Labopin M, Savani B, Hamladji R-M, Beelen D, Mufti G, et al. Intravenous Busulfan Compared with Treosulfan- Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018 Apr;24(4):751–7.
627 628 629 630 631	26.	Saraceni F, Labopin M, Hamladji R-M, Mufti G, Socié G, Shimoni A, et al. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2018 Jan 9;9(3):3379–93.
632 633 634 635	27.	Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980 Aug;69(2):204–17.

636 637 638	28.	Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825–8.
639 640 641 642	29.	Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016 Apr;51(4):610–1.
643 644	30.	Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1(3):255–73.
645 646 647 648	31.	Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999 Jun 30;18(12):1489–500.
649 650 651 652 653 654	32.	Michelis FV, Gupta V, Zhang M-J, Wang H-L, Aljurf M, Bacher U, et al. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017 Jun 1;123(11):2035–42.
655 656 657 658 659 660	33.	Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, et al. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014 Apr;20(4):474–9.
661 662 663 664 665 666	34.	Michelis FV, Atenafu EG, Couban S, Frazer J, Shivakumar S, Hogge DE, et al. Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. Bone Marrow Transplant. 2016;51(7):1019–21.
667 668 669 670	35.	Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Jun 10;28(17):2859–67.
671 672 673 674 675	36.	Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, et al. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 2018 Mar;59(3):601–9.
676 677 678	37.	Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human

679 680 681 682 683		leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Dec 20;24(36):5695–702.
684 685 686 687	38.	Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec 15;110(13):4576–83.
688 689 690	39.	Tiercy J-M, Villard J, Roosnek E. Selection of unrelated bone marrow donors by serology, molecular typing and cellular assays. Transpl Immunol. 2002 Aug;10(2–3):215–21.
691 692 693 694 695 696	40.	Chang Y-J, Wang Y, Liu Y-R, Xu L-P, Zhang X-H, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol OncolJ Hematol Oncol. 2017 Jul 4;10(1):134.
697 698 699	41.	Eapen, M. Unrelated donor transplantation: peripheral blood or bone marrow - does it matter? Best Pract Res Clin Haematol. 27:278–82.
700	42.	Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G,
701 702 703 704 705 706 707		Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018 Sep;93(9):1142– 52.
702 703 704 705 706	43.	regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018 Sep;93(9):1142–
702 703 704 705 706 707 708 709 710 711	43. 44.	regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018 Sep;93(9):1142– 52. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol Off J Am Soc Clin

722 723		induction failure as well as in first or second complete remission. Eur J Haematol. 2016 May;96(5):475–82.
724 725 726 727 728 729 730 731	46.	Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, et al. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017 Feb;23(2):278–84.
732 733 734	47.	Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primer. 2016 10;2:16010.
735 736 737	48.	Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):770–8.
738 739 740	49.	Sallman DA, Lancet JE. What are the most promising new agents in acute myeloid leukemia? Curr Opin Hematol. 2017;24(2):99–107.
741 742 743	50.	Stone RM. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? Best Pract Res Clin Haematol. 2017;30(4):312–6.
744 745 746	51.	Yang D, Zhang X, Zhang X, Xu Y. The progress and current status of immunotherapy in acute myeloid leukemia. Ann Hematol. 2017 Dec;96(12):1965–82.
747 748 749 750 751	52.	Michelis FV, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Lambie A, et al. Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR. Bone Marrow Transplant. 2013 Nov;48(11):1450–5.
752 753 754 755 756 757	53.	Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant. 2015 Nov;50(11):1405–10.
758 759 760 761 762 763	54.	Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015 Aug;21(8):1479–87.

764	Legends
765	Main text tables
766	Table 1 Large Studies of outcome of haemopoietic cell
767	transplant in second complete remission
768	· ·
769	Table 2 Multivariate analysis of outcomes of haemopoietic
770	cell transplant in patients aged under 50 years.
771	aGVHD acute graft versus host disease
772	Allo-HCT allogeneic hematopoietic cell transplant
773	AML acute myeloid leukemia
774	cGVHD chronic graft versus host disease
775	CI confidence interval
776 777	GRFS graft versus host disease and relapse free survival Haplo haploidentical
778	HR hazard ratio
779	KPS Karnofsky performance status
780	LFS Leukaemia free survival
781	MFD matched family donor
782	MMVUD mismatched volunteer unrelated donor
783	NRM Non-relapse mortality
784	OS Overall survival
785	PBSC peripheral blood stem cells
786	RI relapse incidence
787	TCD T cell depletion
788 789	VUD volunteer unrelated donor
790	Table 2 Multivariate analysis of autoemos of hearmon sistic
790 791	Table 3 Multivariate analysis of outcomes of haemopoietic
792	cell transplant in patients aged 50 years or above. aGVHD acute graft versus host disease
793	Allo-HCT allogeneic hematopoietic cell transplant
794	AML acute myeloid leukemia
795	cGVHD chronic graft versus host disease
796	CI confidence interval
797	GRFS graft versus host disease and relapse free survival
798	Haplo haploidentical
799	HR hazard ratio
800	KPS Karnofsky performance status
801	LFS Leukaemia free survival
802	MFD matched family donor MMVUD mismatched volunteer unrelated donor
803 804	NRM Non-relapse mortality
805	OS Overall survival
806	PBSC peripheral blood stem cells
807	RI relapse incidence
808	TCD T cell depletion
809	VUD volunteer unrelated donor
810	

812

- 813 Figure 1
- 814 Outcomes of reduced intensity conditioning (RIC) versus
- 815 myeloablative conditioning (MAC) allogeneic
- 816 haemopoietic cell transplant in patients aged 50 or older.
- 817 (a) Non-relapse mortality (NRM)
- 818 (b) Relapse incidence
- 819 (c) Chronic Graft versus Host disease
- 820 (d) Overall survival (OS)
- 821 (e) Leukaemia-free survival (LFS)
- 822 (f) Graft versus host and relapse free survival (GRFS)

Table 1

Author, Group & Study type	Study population	Outcomes	Conclusions and limitations
Burnet et al (reference 17) UK Medical Research Council	n=1160 Age 16-49y AML patients in first relapse (excluding APL and any prior transplant) Risk stratification by MRC criteria (Grimwade et al 2001 reference 23) Era: 1988-2009	642 (55%) achieved CR2. 314 (27%) had allo-HCT Allo-HCT SY OS from CR2 by MRC risk category: Good: 33% overall, t(8;21) 29% and inv16 39% Intermediate: 47% Adverse: 34% Unknown: 53%	Post-trial analysis with centre defined relapse and reinduction. The benefits of allo-HCT were seen only in those with intermediate or adverse cytogenetic risk groups at diagnosis. Multivariate analysis found that only CR1 duration was significantly associated with survival. Conditioning intensity did not determine outcome. Era coincides with significant changes in HCT practice such as the introduction of reduced intensity conditioning and improvements in supportive care and high resolution HLA typing.
Kurosawa et al(reference 18) Japan retrospectivenational study,	n=931 Age 16-70y AML patients in first relapse (excluding APL and any with prior transplant) Risk stratification by South-West Oncology Group (SWOG) criteria(reference 21). Era 1994-2006	463 (50%) achieved CR2 242 (25%) had allo-HCT in CR2 Allo-HCT 3Y OS from relapse by SWOG cytogenetic risk criteria Overali: 59% Good: t(8:21) 64% and inv16 70% Intermediate: 58% Adverse:67%	The benefits of allo-HCT were only seen in those with intermediate or adverse risk cytogenetic risk groups at diagnosis. Multivariate analysis found that CR1 duration \geq 1y, cytogenetic risk group at diagnosis, white cell count at diagnosis \leq 20 x10 ⁰ /L and CR1 status achieved with first cycle of inducton therapy all predicted survival after relapse. Era coincides with significant changes in HCT practice such as the introduction of reduced intensity conditioning and improvements in supportive care and high resolution HLA typing.
Hospital et al,(reference 19) French AML Intergroup retrospective study	n=145 Age 16-76y AML patients with core-binding factor mutations in first relapse (excluding any with prior transplant). Era 1994-2011	127 (88%) achieved CR2 77 (53%) had allo-HCT in CR2 Allo-HCT 5Y OS 59% and DFS 57% from relapse Incorporation of gemtuzumab ozogamycin (GO) into salvage regimen yielded superior 5Y OS of 82 vs 48% and DFS of 83 vs 44%.	Multivariate analysis found that the benefits of allo-HCT were greater in younger patients, those with inv16/(16;16), longer duration CR1 and use of GO as part of salvage therapy at relapse. Era spans 17 years during which confounders such as experience of RIC-Allo- HCT, supportive care and resolution of HLA matching made significant advances. Residual disease status by molecular and/or immunophenotype was unavailable.
Weisdorf et al(reference 20) Center for International Blood Marrow Transplant Research retrospective study	n=4682 Age \geq 18y AML patients with disease status primary induction failure (PIF) n=1440, median age 52y, relapse failing \geq 1 reinduction cycle (RI) n =1256, median age 49y and CR2 n = 1986, median age 47y. All patients received an allo-HCT Era 2000-2013	Allo-HCT 5Y OS: PIF 21%, RI 18% CR2 39%	Multivariate analysis found that the superior outcomes of allo-HCT in AML CR2 were associated with better performance scores (≥90), longer duration CR1 (+12 months), a history of <i>de novo</i> AML and non-adverse cytogenetics (SWOG criteria). Era spans 13 years during which confounders such as experience of RIC-Allo- HCT, supportive care and resolution of HLA matching made significant advances. Residual disease status by molecular and/or immunophenotype was unavailable.

Table 2

		Relapse			NRM			LFS		
	HR	CI	р	HR	CI	р	HR	CI	р	
Age <50y			-			-				
RIC vs MAC	1.00	0.724 - 1.38	1.00	0.779	0.513 - 1.182	0.24	0.903	0.7 - 1.166	0.43	
Age (per 10 y)	1.05	0.898 - 1.219	0.56	1.245	1.014 - 1.529	0.04	1.114	0.986 - 1.259	0.08	
Time Diagnosis to allo-HCT (m)	0.96	0.948 - 0.975	<10-5	0.999	0.991 - 1.007	0.78	0.982	0.974 - 0.99	10-5	
Cytogenetics										
Good risk group (reference data	1.00			1.00			1.00			
Intermediate	1.52	1.115 - 2.071	0.01	0.922	0.638 - 1.331	0.66	1.266	1.001 - 1.603	0.05	
Adverse	3.347	2.26 - 4.958	<10-5	0.917	0.463 - 1.816	0.80	2.326	1.675 - 3.23	<10-5	
Donor										
MFD (reference data)	1.00			1.00			1.00			
VUD 10/10	0.809	0.578 - 1.131	0.21	1.271	0.802 - 2.014	0.31	0.97	0.74 - 1.27	0.82	
MMUD 9/10	0.842	0.546 - 1.3	0.44	1.986	1.168 - 3.377	0.01	1.189	0.854 - 1.657	0.31	
Haplo	0.576	0.312 - 1.065	0.08	2.096	1.097 - 4.002	0.02	0.944	0.61 - 1.462	0.80	
KPS>80%	1.084	0.497 - 2.362	0.84	0.447	0.219 - 0.914	0.03	0.716	0.424 - 1.207	0.21	
PBSC vs BM	0.714	0.51 - 0.999	0.05	1.599	0.97 - 2.636	0.07	0.957	0.725 - 1.264	0.76	
Year of allo-HCT	1.005	0.953 - 1.06	0.86	0.987	0.922 - 1.057	0.72	1.002	0.961 - 1.045	0.93	
Patient female	0.865	0.659 - 1.135	0.29	0.981	0.693 - 1.389	0.92	0.894	0.723 - 1.107	0.31	
Donor female	0.76	0.574 - 1.006	0.06	1.089	0.77 - 1.539	0.63	0.87	0.701 - 1.081	0.21	
in vivo TCD	1.064	0.767 - 1.475	0.71	0.853	0.564 - 1.289	0.45	0.972	0.752 - 1.256	0.83	
centre			0.25			0.25			0.18	

		OS			GRFS		acute GVHD II-IV				
	HR	CI	р	HR	CI	р	HR	CI	р		
Age <50y											
RIC vs MAC	0.914	0.7 - 1.192	0.507	0.863	0.683 - 1.091	0.217	0.863	0.62 - 1.201	0.381		
Age (per 10 y)	1	0.965 - 1.25	0.155	1.129	1.012 - 1.259	0.030	1.017	0.869 - 1.189	0.838		
Time Diagnosis to allo-HCT (m)	0.982	0.974 - 0.991	<10-4	0.991	0.985 - 0.997	0.003	0.999	0.992 - 1.006	0.763		
Cytogenetics											
Good risk group (reference data	1			1			1				
Intermediate	1.318	1.026 - 1.692	0.031	1.14	0.926 - 1.403	0.217	0.91	0.678 - 1.222	0.531		
Adverse	2.417	1.708 - 3.421	<10-5	1.822	1.344 - 2.471 <10-3		0.804	0.484 - 1.337	0.401		
Donor											
MFD (reference data)	1			1			1				
VUD 10/10	1.044	0.784 - 1.389	0.770	1.049	0.825 - 1.334	0.698	2.057	1.439 - 2.939	<10-4		
MMUD 9/10	1.406	0.997 - 1.983	0.052	1.195	0.881 - 1.622	0.252	2.679	1.721 - 4.17	<10-4		
Haplo	1.217	0.776 - 1.908	0.393	0.692	0.692 0.46 - 1.039		0.076 1.595		0.078		
KPS>80%	0.62	0.371 - 1.035	0.067	0.955	0.574 - 1.588	0.859	0.701	0.356 - 1.378	0.303		
PBSC vs BM	1.087	0.809 - 1.46	0.581	1.252	0.97 - 1.615	0.084	1.203	0.849 - 1.705	0.298		
Year of allo-HCT	0.989	0.946 - 1.035	0.643	1.021	0.983 - 1.06	0.288	0.974	0.927 - 1.023	0.291		
Patient female	0.838	0.667 - 1.053	0.129	0.917	0.758 - 1.109	0.371	0.88	0.668 - 1.161	0.367		
Donor female	0.941	0.749 - 1.183	0.603	0.953	0.787 - 1.154	0.623	0.811	0.613 - 1.074	0.144		
in vivo TCD	0.901	0.692 - 1.173	0.439	0.622	0.492 - 0.786	<10-4	0.479	0.346 - 0.663	<10-4		
centre			0.291			0.090			0.912		


		acute GVHD III-IV	/		chronic GVHD		ext. chronic GVHD				
	HR	CI	р	HR	CI	р	HR	CI	р		
Age <50y											
RIC vs MAC	0.773	0.414 - 1.443	0.418	0.959	0.698 - 1.317	0.795	1.024	0.638 - 1.644	0.922		
Age (per 10 y)	1.129	0.841 - 1.515	0.418	1.049	0.907 - 1.213	0.519	0.999	0.803 - 1.242	0.993		
Time Diagnosis to allo-HCT (m)	1.004	0.993 - 1.014	0.499	1.005	1 - 1.011	0.067	0.997	0.988 - 1.007	0.564		
Cytogenetics											
Good risk group (reference data	1			1			1				
Intermediate	1.011	0.589 - 1.735	0.969	1.011	0.77 - 1.328	0.936	0.904	0.604 - 1.351	0.621		
Adverse	1.03	0.423 - 2.506	0.949	1.354	0.846 - 2.167	0.206	1.187	0.564 - 2.495	0.652		
Donor											
MFD (reference data)	1			1			1				
VUD 10/10	1.844	1.002 - 3.395	0.049	1.205	0.879 - 1.652	0.247	1.27	0.816 - 1.977	0.290		
MMUD 9/10	1.529	0.657 - 3.559	0.324	1.072	0.689 - 1.669	0.758	0.963	0.481 - 1.926	0.914		
Haplo	0.881	0.29 - 2.672	0.823	0.771	0.446 - 1.332	0.351	0.501	0.199 - 1.264	0.143		
KPS>80%	0.477	0.169 - 1.345	0.162	1.608	0.633 - 4.083	0.318	4.276	0.563 - 32.455	0.160		
PBSC vs BM	1.504	0.765 - 2.958	0.237	1.784	1.253 - 2.539	0.001	3.131	1.738 - 5.64	<10-3		
Year of allo-HCT	0.971	0.886 - 1.064	0.528	0.974	0.924 - 1.026	0.315	1.052	0.971 - 1.14	0.213		
Patient female	0.821	0.492 - 1.369	0.450	1.04	0.802 - 1.348	0.768	0.849	0.578 - 1.247	0.404		
Donor female	0.825	0.493 - 1.381	0.465	1.719	1.331 - 2.22	<10-4	1.515	1.047 - 2.194	0.028		
n vivo TCD	0.429	0.24 - 0.769	0.004	0.562	0.411 - 0.77	<10-3	0.27	0.167 - 0.435	<10-5		
centre			0.779			0.076			0.016		


Table 3


		Relapse			NRM		LFS				
	HR	CI	р	HR	CI	р	HR	CI	р		
Age ≥50y											
RIC vs MAC	1.261	0.912 - 1.743	0.161	0.535	0.378 - 0.758	<10-3	0.883	0.695 - 1.122	0.310		
Age (per 10 y)	0.981	0.781 - 1.232	0.868	1.567	1.211 - 2.027	0.001	1.205	1.013 - 1.432	0.035		
Secondary AML	0.857	0.521 - 1.41	0.543	0.99	0.564 - 1.737	0.971	0.916	0.63 - 1.333	0.647		
Time Diagnosis to allo-HCT (m)	0.974	0.963 - 0.986	10-5	1.001	0.992 - 1.01	0.786	0.987	0.98 - 0.995	0.001		
Cytogenetics											
Good risk group (reference data)	1			1			1				
Intermediate	1.436	1.006 - 2.049	0.046	0.869	0.585 - 1.292	0.488	1.163	0.892 - 1.518	0.265		
Adverse	1.79	1.035 - 3.096 0.037		1.108 0.579 - 2.121		0.756	1.465	0.961 - 2.234	0.076		
Donor											
MFD (reference data)	1			1			1				
VUD 10/10	1.097	0.805 - 1.495	0.558	1.237	0.822 - 1.859	0.308	1.146	0.894 - 1.469	0.281		
MMUD 9/10	0.93	0.614 - 1.409	0.733	2.241	1.419 - 3.539	0.001	1.338	0.987 - 1.814	0.061		
Haplo	0.577	0.298 - 1.117	0.103	1.948	1.069 - 3.552	0.029	1.017	0.657 - 1.574	0.941		
KPS >80%	0.867	0.472 - 1.592	0.646	0.265	0.162 - 0.435	<10-5	0.486	0.331 - 0.715	<10-3		
PBSC vs BM	0.998	0.635 - 1.568	0.992	1.325	0.825 - 2.128	0.244	1.117	0.804 - 1.553	0.509		
Year of allo-HCT	0.985	0.935 - 1.037	0.556	0.943	0.889 - 1.001	0.054	0.968 0.93 - 1.007		0.104		
Patient female	0.747	0.575 - 0.971	0.029	0.825	0.608 - 1.12	0.218	0.774	0.633 - 0.945	0.012		
Donor female	0.909	0.687 - 1.203	0.505	1.027	0.745 - 1.415	0.869	0.95	0.768 - 1.174	0.634		
in vivo TCD	1.028	0.761 - 1.389	0.859	1.047	0.746 - 1.468	0.792	1.042	0.826 - 1.315	0.727		
centre			0.228			0.256			0.188		

		OS			GRFS		acute GVHD II-IV				
	HR	CI	р	HR	CI	р	HR	CI	р		
Age ≥50y											
RIC vs MAC	0.915	0.713 - 1.175	0.489	1.04	0.832 - 1.299	0.733	0.921	0.648 - 1.307	0.644		
Age (per 10 y)	1.265	1.056 - 1.516	0.011	1.017	0.865 - 1.196	0.840	0.927	0.717 - 1.197	0.559		
Secondary AML	0.955	0.646 - 1.412	0.819	1.061	0.755 - 1.491	0.734	1.506	0.92 - 2.467	0.104		
Time Diagnosis to allo-HCT (m)	0.988	0.98 - 0.996	0.002	0.993	0.986 - 1	0.037	1.004	0.996 - 1.012	0.357		
Cytogenetics											
Good risk group (reference data)	1			1			1				
Intermediate	1.202	0.903 - 1.6	0.206	1.192	0.934 - 1.521	0.159	1.031	0.685 - 1.552	0.883		
Adverse	1.607	1.042 - 2.479	0.032	1.31	0.879 - 1.954	0.185	0.833	0.403 - 1.724	0.623		
Donor											
MFD (reference data)	1			1			1				
VUD 10/10	1.183	0.909 - 1.54	0.210	1.137	0.906 - 1.426	0.267	1.68	1.118 - 2.525	0.013		
MMUD 9/10	1.511	1.098 - 2.081 0.011		1.516	1.146 - 2.004	0.004	2.685	1.692 - 4.26	<10-4		
Haplo	1.321	0.842 - 2.074	0.226	1.016 0.681 - 1.517		0.937	2.434	1.341 - 4.417	0.003		
KPS >80%	0.437	0.297 - 0.645	<10-4	0.363	0.254 - 0.518	0.000	0.562	0.322 - 0.982	0.043		
PBSC vs BM	1.167	0.827 - 1.649	0.379	1.172	0.863 - 1.593	0.309	1.331	0.809 - 2.191	0.260		
Year of allo-HCT	0.968	0.927 - 1.01	0.133	0.97	0.936 - 1.007	0.108	0.986	0.932 - 1.043	0.622		
Patient female	0.828	0.672 - 1.022	0.078	0.884	0.735 - 1.062	0.188	1.044	0.779 - 1.4	0.771		
Donor female	1.008	0.808 - 1.259	0.941	1.065	0.88 - 1.29	0.516	0.919	0.669 - 1.261	0.599		
in vivo TCD	1.082	0.853 - 1.371	0.516	0.764	0.617 - 0.945	0.013	0.93	0.659 - 1.312	0.679		
centre			0.312			0.120			0.263		

		acute GVHD III-IV	/		chronic GVHD		ext. chronic GVHD				
	HR	CI	р	HR	CI	р	HR	CI	р		
Age ≥50y			-			-			-		
RIC vs MAC	0.729	0.428 - 1.242	0.245	1.377	1.027 - 1.845	0.032	1.352	0.869 - 2.102	0.181		
Age (per 10 y)	0.71	0.469 - 1.075	0.106	0.863	0.698 - 1.067	0.173	0.79	0.571 - 1.093	0.155		
Secondary AML	1.669	0.78 - 3.573	0.187	0.933	0.57 - 1.527	0.782	1.45	0.741 - 2.838	0.279		
Time Diagnosis to allo-HCT (m)	1.008	0.997 - 1.02	0.143	0.996	0.988 - 1.003	0.249	1.005	0.995 - 1.015	0.316		
Cytogenetics											
Good risk group (reference data)	1			1			1				
Intermediate	1.082	0.574 - 2.043	0.807	1.161	0.843 - 1.599	0.359	1.064	0.667 - 1.7	0.794		
Adverse	0.357	0.079 - 1.614	0.181	1.583	0.917 - 2.732	0.917 - 2.732 0.099		0.435 - 2.639	0.881		
Donor											
MFD (reference data)	1			1			1				
VUD 10/10	1.293	0.669 - 2.5	0.445	0.983	0.738 - 1.311	0.909	1.388	0.892 - 2.159	0.146		
MMUD 9/10	4.167	2.125 - 8.173	<10-4	1.006	0.678 - 1.493	0.975	1.741	0.992 - 3.056	0.054		
Haplo	1.811	0.717 - 4.572	0.209	0.86	0.508 - 1.455	0.575	0.585	0.234 - 1.464	0.252		
<ps>80%</ps>	0.338	0.152 - 0.748	0.007	0.758	0.432 - 1.33	0.333	0.66	0.261 - 1.671	0.381		
PBSC vs BM	1.441	0.679 - 3.06	0.341	1.683	1.08 - 2.624	0.021	1.599	0.814 - 3.144	0.173		
Year of allo-HCT	0.994	0.909 - 1.086	0.886	0.985	0.939 - 1.034	0.543	1.004	0.933 - 1.081	0.905		
Patient female	1.114	0.704 - 1.762	0.644	1.137	0.886 - 1.458	0.313	1.08	0.743 - 1.571	0.686		
Donor female	1.107	0.686 - 1.787	0.676	1.034	0.795 - 1.344	0.804	1.558	1.065 - 2.28	0.022		
n vivo TCD	0.747	0.44 - 1.269	0.281	0.484	0.373 - 0.627	0.000	0.266	0.18 - 0.393	<10-5		
entre			0.283			0.271			0.921		








Ε

RIC

F

RIC

GRFS



			Time from transplant (years)								Time from transplant (years)							Time from transplant (years)			
number of at-risk patients								number of at-risk patients					number of at-risk patients								
— мас	314	147	90	61	50	31	MAC	314	147	90	61	50	36	MAC	308	119	71	46	35	25	
- RIC	625	296	209	147	106	8'	RIC	625	296	209	147	106	81	RIC	600	223	154	108	78	57	